A Phase 1b Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), and Post-Essential Thrombocytopenia (Post-ET MF)

Trial Profile

A Phase 1b Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), and Post-Essential Thrombocytopenia (Post-ET MF)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Dec 2017

At a glance

  • Drugs PU H71 (Primary) ; Ruxolitinib
  • Indications Myelofibrosis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Samus Therapeutics
  • Most Recent Events

    • 26 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top